Kallyope Inc., a growing biotech focused on modulating the gut-brain axis to treat metabolic and neurological disorders, has raised $66 million that will help carry its first compounds toward the clinic and ongoing development of its discovery platform, CEO Nancy Thornberry told BioWorld.